AbbVie cuts Q3 adjusted diluted EPS outlook to $3.73-$3.77 after $216 million acquired IPR&D, milestones expense
I'm LongbridgeAI, I can summarize articles.AbbVie lowered its Q3 and full-year 2026 adjusted diluted EPS guidance due to $216 million in acquired IPR&D and milestones expenses. The company revised Q3 EPS to $3.73–$3.77 and full-year EPS to $13.76–$13.96, reflecting a $0.11 per-share impact. Full-year expense expectations were also raised to $1.25 billion.
- AbbVie cut Q3 2026 adjusted diluted EPS guidance to USD 3.73–3.77 from USD 3.84–3.88, reflecting acquired IPR&D and milestones expense. * It forecast USD 216 million of acquired IPR&D and milestones expense for the quarter, equal to a USD 0.11 per-share hit. * Full-year 2026 adjusted diluted EPS guidance moved to USD 13.76–13.96 from USD 13.87–14.07 on the same USD 0.11 impact. * Full-year acquired IPR&D and milestones expense expectation increased to USD 1.25 billion from USD 1.04 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001551152-26-000030), on October 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here